Siga Technologies (SIGA) Income from Continuing Operations (2010 - 2025)
Siga Technologies' (SIGA) quarterly Income from Continuing Operations came in at 6365819.0 in Q3 2025, down 573.67% YoY from 1343945.0 in Q3 2024, and down 117.95% on a QoQ basis from 35472173.0 in Q2 2025.
Siga Technologies (SIGA) Income from Continuing Operations (2010 - 2025) Analysis & Trends
Siga Technologies (SIGA) has 16 years of Income from Continuing Operations data on file, last reported at 6365819.0 in Q3 2025.
- Quarterly Income from Continuing Operations fell 573.67% year-over-year to 6365819.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 74496254.0 (down 7.89% YoY) and the FY2024 annual result came in at 59214216.0, down 6.41% from the prior year.
- Income from Continuing Operations eased to 6365819.0 in Q3 2025, from 35472173.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 73207028.0 in Q4 2021 to a low of 6365819.0 in Q3 2025.
- A 5-year average of 13195645.32 and a median of 167606.0 in 2021 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 1873.05% in 2025, down 573.67% in 2025.
- Tracing SIGA's Income from Continuing Operations over 5 years: stood at 73207028.0 in 2021, then tumbled by 106.34% to 4639572.0 in 2022, then jumped by 1553.97% to 67457892.0 in 2023, then tumbled by 32.16% to 45760315.0 in 2024, then sank by 113.91% to 6365819.0 in 2025.
- The last three Income from Continuing Operations figures came in at 6365819.0 (Q3 2025), 35472173.0 (Q2 2025), and 370415.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Siga Technologies | 211.95 Mn | 56.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -6.37 Mn |
| Jun 30, 2025 | 35.47 Mn |
| Mar 31, 2025 | -370,415.00 |
| Dec 31, 2024 | 45.76 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 10.28 Mn |
| Dec 31, 2023 | 67.46 Mn |
| Sep 30, 2023 | -393,066.00 |
| Jun 30, 2023 | -2.85 Mn |
| Mar 31, 2023 | -917,677.00 |
| Dec 31, 2022 | -4.64 Mn |
| Sep 30, 2022 | 33.03 Mn |
| Jun 30, 2022 | 1.99 Mn |
| Mar 31, 2022 | -361,049.00 |
| Dec 31, 2021 | 73.21 Mn |
| Sep 30, 2021 | -3.08 Mn |
| Jun 30, 2021 | 167,606.00 |
| Mar 31, 2021 | -812,105.00 |
| Dec 31, 2020 | 20.18 Mn |